Current Diabetes Reports

, Volume 10, Issue 4, pp 257–260 | Cite as

Use of Medications to Lower Urine Protein Level in Patients With Diabetic Kidney Disease

Clinical Trial Report



No potential conflict of interest relevant to this article was reported.


  1. 1.
    ONTARGET Investigators, Yusuf S, Teo KK, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.CrossRefPubMedGoogle Scholar
  2. 2.
    Schwab SJ, Christensen RL, Dougherty K, Klahr S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987, 147:943–944.CrossRefPubMedGoogle Scholar
  3. 3.
    Ninomiya T, Perkovic V, de Galan BE, et al.: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813–1821.CrossRefPubMedGoogle Scholar
  4. 4.
    Gerstein HC, Mann JF, Yi Q, et al.: Events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426.CrossRefPubMedGoogle Scholar
  5. 5.
    Mauer M, Zinman B, Gardiner R, et al.: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Slagman MC, Navis G, Laverman D: Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Curr Opin Nephrol Hypertens 2010, 19:140–152.CrossRefPubMedGoogle Scholar
  7. 7.
    Chatzikyrkou C, Menne J, Haller H: How to achieve renal protection in light of ONTARGET? J Hypertens 2009, 27(Suppl 2):S15–S17.CrossRefGoogle Scholar
  8. 8.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.CrossRefPubMedGoogle Scholar
  9. 9.
    Krum H, Carson P, Farsang C, et al.: Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004, 6:937–945.CrossRefPubMedGoogle Scholar
  10. 10.
    Blacher J, Amah G, Girerd X, et al.: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997, 10:1326–1334.CrossRefPubMedGoogle Scholar
  11. 11.
    Duprez DA, De Buyzere ML, Rietzschel ER, et al.: Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998, 19:1371–1376.CrossRefPubMedGoogle Scholar
  12. 12.
    Farquharson, CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594–597.PubMedGoogle Scholar
  13. 13.
    Tian WN, Braunstein LD, Pang J, et al.: Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem 1998, 273:10609–10617.CrossRefPubMedGoogle Scholar
  14. 14.
    Tian WN, Braunstein LD, Apse K, et al.: Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol 1999, 276:C1121–C1131.PubMedGoogle Scholar
  15. 15.
    Zhang Z, Apse K, Pang J, Stanton RC: High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 2000, 275:40042–40047.CrossRefPubMedGoogle Scholar
  16. 16.
    Xu Y, Osborne B, Stanton RC: Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of protein kinase A which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol 2005, 289:F1040–F1047.CrossRefPubMedGoogle Scholar
  17. 17.
    Leopold JA, Dam A, Scribner AW, et al.: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007, 13:189–197.CrossRefPubMedGoogle Scholar
  18. 18.
    Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.CrossRefPubMedGoogle Scholar
  19. 19.
    Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991–2002.CrossRefPubMedGoogle Scholar
  20. 20.
    McCormick BB, Sydor A, Akbari A, et al.: The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008, 52:454–463.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of NephrologyJoslin Diabetes CenterBostonUSA

Personalised recommendations